Objective
to report the clinical outcomes of a strategy using TAVR or clinical aortic stenosis surveillance (CAS) and aortic valve replacement upon progression to severe aortic stenosis for treatment of patients with aortic stenosis
Study
investigator-initiated, multicenter randomised trial
Population
patients with NYHA II to IV, LVEF 20-50% and moderate aortic stenosis
Endpoints
hierarchical occurrence of 1) all cause death 2) disabling stroke 3)hospitalisation and 4) change from baseline KCCQ-OSS
Conclusion
TAVR was not superior to surveillance in patients with systolic heart failure and moderate aortic stenosis
van Mieghem et al. J Am Coll Cardiol. 2024; October 28 online
